Suppr超能文献

内镜经蝶窦手术治疗肢端肥大症患者中肿瘤特征及术前术后激素水平对激素缓解的影响。

Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.

机构信息

1Department of Neurosurgery, USC Pituitary Center, Keck School of Medicine of University of Southern California, Los Angeles, California.

2Department of Neurosurgery, Medical University of Vienna, Austria.

出版信息

Neurosurg Focus. 2020 Jun;48(6):E10. doi: 10.3171/2020.3.FOCUS2080.

Abstract

OBJECTIVE

Acromegaly is a disease of acral enlargement and elevated serum levels of insulin-like growth factor-1 (IGF-1) and growth hormone (GH), usually caused by a pituitary adenoma. A lack of consensus on factors that reliably predict outcomes in acromegalic patients following endoscopic endonasal transsphenoidal surgery (EETS) warrants additional investigation.

METHODS

The authors identified 52 patients with acromegaly who underwent an endoscopic endonasal approach (EEA) for resection of a GH-secreting pituitary adenoma. Preoperative and postoperative tumor and endocrinological characteristics such as tumor size, invasiveness, and GH/IGF-1 levels were evaluated as potential indicators of postoperative hormonal remission. Endocrinological remission was defined as postoperative IGF-1 levels at or below the age- and sex-normalized values.

RESULTS

The 52 patients had a mean age of 50.7 ± 13.4 years and a mean follow-up duration of 24.4 ± 19.1 months. Ten patients (19%) had microadenomas and 42 (81%) had macroadenomas. Five patients (9.6%) had giant adenomas. Forty-four tumors (85%) had extrasellar extension, with 40 (77%) exhibiting infrasellar invasion, 18 (35%) extending above the sella, and 7 (13%) invading the cavernous sinuses. Thirty-six patients (69%) underwent gross-total resection (GTR; mean maximal tumor diameter 1.47 cm), and 16 (31%) underwent subtotal resection (STR; mean maximal tumor diameter 2.74 cm). Invasive tumors were significantly larger, and Knosp scores were negatively correlated with GTR. Thirty-eight patients (73%) achieved hormonal remission after EEA resection alone, which increased to 87% with adjunctive medical therapy. Ninety percent of patients with microadenomas and 86% of patients with macroadenomas achieved hormonal remission. Preoperative IGF-1 and postoperative day 1 (POD1) GH levels were inversely correlated with hormonal remission. Postoperative CSF leakage occurred in 2 patients (4%), and none experienced vision loss, death, or injury to internal carotid arteries or cranial nerves.

CONCLUSIONS

Endoscopic transsphenoidal resection of GH-secreting pituitary adenomas is a safe and highly effective treatment for achieving hormonal remission and tumor control in up to 87% of patients with acromegaly when combined with postoperative medical therapy. Patients with lower preoperative IGF-1 and POD1 GH levels, with less invasive pituitary adenomas, and who undergo GTR are more likely to achieve postoperative biochemical remission.

摘要

目的

肢端肥大症是一种肢端增大和血清胰岛素样生长因子-1(IGF-1)和生长激素(GH)水平升高的疾病,通常由垂体腺瘤引起。内镜经鼻蝶入路(EETS)治疗后,预测肢端肥大症患者结局的可靠因素尚未达成共识,仍需要进一步研究。

方法

作者纳入了 52 例接受内镜经鼻蝶入路(EEA)切除 GH 分泌性垂体腺瘤的肢端肥大症患者。评估了术前和术后肿瘤和内分泌特征,如肿瘤大小、侵袭性和 GH/IGF-1 水平,作为术后激素缓解的潜在指标。内分泌缓解定义为术后 IGF-1 水平达到或低于年龄和性别正常化值。

结果

52 例患者的平均年龄为 50.7±13.4 岁,平均随访时间为 24.4±19.1 个月。10 例(19%)患者为微腺瘤,42 例(81%)为大腺瘤。5 例(9.6%)患者为巨大腺瘤。44 例(85%)肿瘤有鞍外扩展,其中 40 例(77%)有鞍下侵犯,18 例(35%)肿瘤向上突入鞍上,7 例(13%)侵犯海绵窦。36 例(69%)患者行大体全切除(GTR;平均最大肿瘤直径 1.47cm),16 例(31%)行次全切除(STR;平均最大肿瘤直径 2.74cm)。侵袭性肿瘤明显更大,Knosp 评分与 GTR 呈负相关。38 例(73%)患者在 EEA 切除术后单独获得激素缓解,联合辅助药物治疗后增至 87%。90%的微腺瘤患者和 86%的大腺瘤患者获得激素缓解。术前 IGF-1 和术后第 1 天(POD1)GH 水平与激素缓解呈负相关。2 例(4%)患者发生术后脑脊液漏,无视力丧失、死亡或颈内动脉或颅神经损伤。

结论

内镜经蝶窦切除 GH 分泌性垂体腺瘤是一种安全、有效的治疗方法,当与术后药物治疗联合使用时,高达 87%的肢端肥大症患者可实现激素缓解和肿瘤控制。术前 IGF-1 和 POD1 GH 水平较低、侵袭性较小的垂体腺瘤和 GTR 患者术后更有可能获得生化缓解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验